Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops treatments for metabolic and endocrine disorders. The company's lead clinical program is VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, which is being evaluated in late-stage trials for obesity in both subcutaneous and oral formulations. Viking's pipeline also includes VK2809, an orally available, small molecule selective thyroid hormone receptor beta agonist for lipid and metabolic disorders such as non-alcoholic steatohepatitis (NASH). Additionally, the company is developing VK0214 for X-linked adrenoleukodystrophy (X-ALD) and VK5211 for patients recovering from non-elective hip fracture surgery. Operating primarily in the United States, Viking utilizes an in-house research model to advance its candidates through clinical trials with the goal of eventual regulatory approval or strategic partnerships.
